Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...

Replimune stock was down 76.88% in pre-market trading on Tuesday, following a 1.94% rally yesterday. The company’s shares ...

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL) resulting from ...

Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the ...

Replimune Group Stock Performance. Shares of REPL stock opened at $8.76 on Friday. The company’s fifty day simple moving average is $8.69 and its 200-day simple moving average is $11.24.

Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price […] Replimune Group, Inc. (NASDAQ:REPL ...

Replimune Group granted stock options and restricted shares to ten new non-executive employees as part of their incentive plan. Replimune Group, Inc., a clinical stage biotechnology company based ...

Research and development expenses included $4.5 million in stock-based compensation expenses for the fiscal fourth quarter and $18.4 million for the fiscal year ended March 31, 2025.